(MENAFN- GlobeNewsWire - Nasdaq) Boost ROI with AI/ML, CRO outsourcing, cloud data management, faster formulation, end-to-end platforms, and local sourcing to cut costs and time-to-market.Dublin, Oct. 19, 2026 (GLOBE NEWSWIRE) -- "Drug Development Services Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Drug Development Services Market Set to Reach $50.26 Billion by 2030 as Personalized Medicine and AI Adoption Accelerate
The global drug development services market is experiencing rapid expansion as pharmaceutical and biotechnology companies increase research investment, outsource complex development activities, and pursue more efficient pathways from discovery to commercialization. The market is projected to grow from $28.09 billion in 2025 to $31.5 billion in 2026, representing a compound annual growth rate (CAGR) of 12.2%.
Historical market growth has been supported by rising pharmaceutical research and development expenditure, greater outsourcing of drug development services, and the increasing prevalence of chronic and infectious diseases. More stringent regulatory compliance requirements and advances in molecular biology and in vitro testing have also strengthened demand for specialist development capabilities.
Looking ahead, the drug development services market is forecast to reach $50.26 billion by 2030 at a CAGR of 12.4%. Key growth drivers include the adoption of artificial intelligence and machine learning in drug discovery, the expansion of biologics and personalized medicine pipelines, and rising demand for contract research organizations. Cloud-based clinical data management and increased drug development activity in emerging markets are also expected to create significant opportunities.
Precision and personalized medicine remain central to the market's growth trajectory. Advances in genomic technologies are improving diagnosis, patient stratification, and targeted treatment selection, creating demand for specialized services that support the design, testing, and validation of therapies for distinct genetic and molecular profiles. In February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. This increase highlights the growing importance of tailored therapies within pharmaceutical pipelines.
Innovation in formulation development is another major drug development services market trend. Service providers are introducing science-driven platforms designed to accelerate early-stage formulation, improve bioavailability, and reduce development timelines for complex drug candidates. In May 2025, Aenova Group GmbH launched its Aenovation program to support the early development of pharmaceutical formulations, particularly poorly soluble compounds. The program combines active pharmaceutical ingredient profiling, developability classification, rapid prototype selection, solubility-enhancement technologies, and transfer to good manufacturing practice laboratory and pilot-scale manufacturing.
By enabling more efficient formulation strategies and earlier production of materials for first-in-human trials, these platforms can help pharmaceutical innovators and biotechnology start-ups conserve resources while advancing promising therapies into clinical development. Such capabilities are becoming increasingly important as pipelines include more complex molecules with challenging formulation and delivery requirements.
Merger and acquisition activity is also reshaping the competitive landscape as providers seek to build integrated, end-to-end drug development platforms. In September 2025, Symeres B.V. acquired DGr Pharma for an undisclosed amount. The transaction expanded Symeres' early-phase development and regulatory capabilities, strengthening its ability to provide coordinated services to biopharmaceutical clients.
Tariffs continue to influence the drug development services industry by increasing the cost of imported laboratory equipment, reagents, specialized chemicals, and other materials required for preclinical and clinical testing. Drug metabolism, medicinal chemistry, and biological services are among the segments most exposed to these cost pressures. The effects are particularly evident in North America and Europe, where many organizations depend on internationally sourced research materials and specialized equipment.
At the same time, shifting procurement strategies may generate opportunities for domestic suppliers, regional contract research organizations, and research institutes. Increased local sourcing could encourage service providers to expand laboratory capacity, strengthen supply chain resilience, and offer a broader range of development capabilities closer to pharmaceutical and biotechnology customers.
Market demand spans drug metabolism and pharmacokinetics, biological services, medicinal chemistry, candidate validation, lead optimization, hit-to-lead programs, target validation, and target selection. Services support biologics, small molecules, and infectious disease diagnostics across therapeutic areas including oncology, neurology, cardiovascular disease, digestive system disorders, immunology, and infectious diseases.
Pharmaceutical companies, biotechnology businesses, contract research organizations, and academic research institutions rely on these services throughout preclinical research, toxicology and safety assessment, clinical data management, biostatistics, regulatory submissions, pharmacovigilance, quality assurance, and compliance. Continued investment in these capabilities, combined with AI-enabled discovery and increasingly sophisticated therapeutic pipelines, is expected to sustain strong drug development services market growth through 2030.
Markets Covered:
1) By Type: Drug Metabolism and Pharmacokinetics; Biological Services; Medicinal Chemistry
2) By Process: Candidate Validation; Lead Optimization; Hit To Lead Identification; Target Validation; Target Selection
3) By Drug: Biologics; Infectious Disease Diagnostics; Small Molecules
4) By Therapeutic Area: Cardiovascular Disease; Digestive System Disease; Immune System and Infectious Disease; Neurology; Oncology; Other Therapeutic Areas
5) By End User: Pharmaceutical Companies; Biotechnology Companies; Contract Research Organizations; Academic and Research Institutes
Subsegments:
1) By Drug Metabolism and Pharmacokinetics: Absorption Studies; Distribution Studies; Metabolism Studies; Excretion Studies; Bioavailability Assessment; Drug Drug Interaction Studies
2) By Biological Services: Cell Based Assays; Molecular Biology Services; Protein Expression and Purification; Biomarker Discovery; In Vitro Pharmacology
3) By Medicinal Chemistry: Compound Design and Synthesis; Structure Activity Relationship Studies; Lead Optimization Chemistry; Chemical Library Development; Process Chemistry Development
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment